Skip to main content
. 2013 Dec;61(12):705–710. doi: 10.4103/0301-4738.124750

Figure 2.

Figure 2

Phase contrast microscopy images of ARPE-19 cells after 5 days exposure to bevacizumab shows healthy cells. (a) Untreated control ARPE-19 cells. (b) IgG-treated (1 mg/ml) control ARPE-19 cells. (c) ARPE-19 cells treated with 1 mg/ml bevacizumab. ×40